In a 67-year-old male with autism spectrum disorder who is taking mirtazapine 30 mg at bedtime and sertraline 50 mg daily, what medication can be added to manage behavioral outbursts such as yelling and self‑injurious tongue biting?

Atypical Antipsychotics for Behavioral Outbursts in Autism Spectrum Disorder

For this 67-year-old male with autism spectrum disorder experiencing behavioral outbursts (yelling and self-injurious tongue biting), add low-dose risperidone starting at 0.25 mg at bedtime or aripiprazole starting at 2.5-5 mg at bedtime to his current regimen.

Rationale for Atypical Antipsychotics

The behavioral outbursts described—yelling and self-injurious behavior (tongue biting)—represent irritability and aggression, which are FDA-approved indications for atypical antipsychotics in autism spectrum disorder. Risperidone and aripiprazole are the only two medications with FDA approval specifically for irritability associated with ASD 1, 2.

While guidelines for intellectual disability recommend these agents for severe agitation and self-injury 3, the evidence is strongest in the autism population. A 2023 Cochrane review found that atypical antipsychotics probably reduce irritability with a large effect size (SMD -0.90) and may reduce self-injury with a very large effect size (SMD -1.43) at short-term follow-up 1.

Specific Medication Selection

First-Line Options:

Risperidone:

• Start: 0.25 mg at bedtime 4
• Titrate slowly in 0.25-0.5 mg increments every 5-7 days
• Target dose: 0.5-2 mg daily (divided doses if needed)
• Maximum: 2-3 mg daily 4
• Advantage: Most robust evidence base, longer track record
• Caution: Extrapyramidal symptoms may occur at ≥2 mg daily 4

Aripiprazole:

• Start: 2.5-5 mg at bedtime 5, 3
• Titrate by 2.5-5 mg increments weekly
• Target dose: 5-15 mg daily
• Maximum: Generally 10-15 mg daily
• Advantage: Lower risk of metabolic side effects, less sedation 1

Critical Monitoring Requirements

Given this patient's age (67 years), monitor closely for:

Metabolic effects:

• Weight gain and increased appetite (common with both agents) 1
• Fasting glucose and lipid panel at baseline, 3 months, then quarterly
• Blood pressure monitoring

Neurological effects:

• Extrapyramidal symptoms (tremor, rigidity, akathisia)
• Sedation and dizziness (fall risk in elderly) 4, 5
• Tardive dyskinesia risk increases with age and duration of use

Cardiovascular effects:

• Baseline ECG recommended given age
• Monitor for QTc prolongation 4
• Orthostatic hypotension (particularly with risperidone)

Why Not Other Options?

Current medications (mirtazapine 30 mg, sertraline 50 mg):

• Already on board; sertraline has no evidence for reducing irritability in ASD 1, 6
• Mirtazapine primarily targets depression/anxiety, not behavioral outbursts 7
• Both carry serotonin syndrome risk when combined, though current doses are moderate 7, 8

ADHD medications (stimulants, atomoxetine, alpha-2 agonists):

• May reduce irritability slightly (SMD -0.20) 1
• Better for hyperactivity/inattention than aggression
• Not appropriate for primary self-injury and severe behavioral outbursts 2
• Clonidine/guanfacine could be considered as adjuncts if hyperactivity is prominent 3, 2

SSRIs (increasing sertraline):

• Evidence shows SSRIs are poorly tolerated in ASD and lack efficacy for behavioral symptoms 9, 10
• May cause behavioral activation/agitation, particularly problematic here 11
• Current dose of 50 mg is already therapeutic for anxiety if that were the target

Benzodiazepines:

• Not recommended for chronic behavioral management in intellectual/developmental disabilities 3
• Risk of disinhibition, paradoxical agitation, and dependence
• Only appropriate for acute crisis situations 12

Implementation Strategy

1. Before starting: Rule out medical causes of behavioral change (pain, infection, constipation, medication side effects from current regimen)

2. Initiate treatment: Choose risperidone 0.25 mg at bedtime OR aripiprazole 2.5 mg at bedtime based on:

   • Risperidone if sedation would be beneficial (given bedtime dosing already established)
   • Aripiprazole if metabolic concerns are paramount

3. Titration schedule:

   • Increase every 5-7 days based on response and tolerability
   • Target lowest effective dose
   • Most patients respond to risperidone 1-2 mg daily or aripiprazole 5-10 mg daily

4. Response assessment:

   • Expect improvement in 4-6 weeks at therapeutic dose
   • Use structured rating scales (Aberrant Behavior Checklist-Irritability subscale)
   • Document frequency/severity of yelling and self-injury

5. Long-term management:

   • Attempt dose reduction after 6-12 months of stability 1
   • Continue monitoring for metabolic and neurological adverse effects
   • Consider behavioral interventions concurrently 13

Common Pitfalls to Avoid

• Dosing too high too fast: Elderly patients with ASD may be more sensitive to side effects; start low, go slow
• Polypharmacy without indication: Don't add multiple agents simultaneously; assess response to one medication first
• Ignoring metabolic monitoring: Weight gain and metabolic syndrome are significant long-term risks
• Using benzodiazepines chronically: May worsen behavioral dyscontrol in this population
• Assuming SSRIs will help behavioral outbursts: They won't, and may worsen agitation in ASD